Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases

International Journal of Antimicrobial Agents

Volumn 30, Issue 6, 2007, Pages 537-540

  Tripodi, Marie Francoise ^a   Durante Mangoni, Emanuele ^a   Fortunato, Rosaria ^a   Utili, Riccardo ^a   Zarrilli, Raffaele ^b,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Acinetobacter; Colistin; OXA 58 carbapenemase; Rifampicin; Time kill assay

Indexed keywords

BACTERIAL ENZYME; COLISTIN; IMIPENEM; OXA 58 CARBAPENEMASE; RIFAMPICIN; SULTAMICILLIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME SYNTHESIS; ITALY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMPICILLIN; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; COLISTIN; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; IMIPENEM; ITALY; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; SULBACTAM;

EID: 35748930554     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.07.007     Document Type: Article

References (15)

1. Bergogne-Berezin E., and Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9 (1996) 148-165
2. Bonomo R.A., and Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43 Suppl. 2 (2006) S49-S56
3. Zarrilli R., Crispino M., Bagattini M., et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol 42 (2004) 946-953
4. Heritier C., Poirel L., Lambert T., et al. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 49 (2005) 3198-3202
5. Bertini A., Giordano A., Varesi P., et al. First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy. Antimicrob Agents Chemother 50 (2006) 2268-2269
6. Zarrilli R., Casillo R., Di Popolo A., et al. Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy. Clin Microbiol Infect 13 (2007) 481-489
7. Yoon J., Terzian C., Mariano N., et al. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48 (2004) 753-757
8. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F.J., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 (2003) 1111-1118
9. Montero A., Ariza J., Corbella X., et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54 (2004) 1085-1091
10. Petrosillo N., Chinello P., Proietti M.F., et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11 (2005) 682-683
11. Pachon-Ibanez M.E., Fernandez-Cuenca F., Docobo-Perez F., et al. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 58 (2006) 689-692
12. Giamarellos-Bourbolis E.J., Xirouchaki E., and Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 40 (2001) 117-120
13. Motaouakkil S., Charra B., Hachimi A., et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 53 (2006) 274-278
14. Wareham D.W., and Bean D.C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 5 (2006) 10
15. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved standard M7-A6. Wayne, PA: CSLI; 2005.